Jeddi Sajad, Kashfi Khosrow, Ghasemi Asghar
Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, United States.
Front Endocrinol (Lausanne). 2025 Jun 12;16:1480838. doi: 10.3389/fendo.2025.1480838. eCollection 2025.
Approximately 28% of individuals with diabetes have osteoporosis. Diabetoporosis, which refers to the diabetes-related decrease in bone quality and quantity, increases the risk of osteoporotic fractures by 600-700% in individuals with type 1 diabetes (T1D) and by 38-70% in those with type 2 diabetes (T2D) compared to non-diabetic individuals. Decreased nitric oxide (NO) bioavailability contributes to diabetoporosis. This review summarizes the potential role of nitrate as a NO donor in preventing and treating diabetic osteoporosis. Evidence suggests that organic and inorganic nitrates have anti-osteoporotic effects in animal models of osteoporosis, as demonstrated by increasing bone mineral density (BMD, 3-42%) and bone weight (6-160%). Observational human studies indicate a lower fracture risk (6-17%) and a higher BMD (3-5%) following organic nitrate administration. Similar protective effects (7-74% reduction in fracture risk and 8-84% increase in BMD) have been observed with nitrate-rich diets. Randomized controlled trials have also shown that nitrate increases circulating bone formation markers; however, no effect on fracture risk has been reported, and increased BMD (8.8%) was reported only in one study. Nitrate converts to nitrite and then to NO (exogenous NO), increasing NO bioavailability in bone. In addition, nitrate increases the expression of endothelial NO synthase (eNOS), thereby increasing the endogenous NO in bone. Nitrate-derived NO promotes bone formation and reduces bone resorption via the NO/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) signaling pathway. In addition to increasing NO availability, nitrate may enhance plasma insulin levels, reduce hyperglycemia, and improve insulin resistance in diabetes, further contributing to nitrates' anti-osteoporotic effects in diabetic bone. In conclusion, NO-based interventions such as nitrate may have a potential role in preventing and treating diabetoporosis.
约28%的糖尿病患者患有骨质疏松症。糖尿病性骨质疏松症是指与糖尿病相关的骨质量和骨量下降,与非糖尿病个体相比,1型糖尿病(T1D)患者发生骨质疏松性骨折的风险增加600 - 700%,2型糖尿病(T2D)患者增加38 - 70%。一氧化氮(NO)生物利用度降低会导致糖尿病性骨质疏松症。本综述总结了硝酸盐作为NO供体在预防和治疗糖尿病性骨质疏松症中的潜在作用。有证据表明,有机和无机硝酸盐在骨质疏松症动物模型中具有抗骨质疏松作用,表现为骨矿物质密度(BMD,增加3 - 42%)和骨重量(增加6 - 160%)。观察性人体研究表明,服用有机硝酸盐后骨折风险降低(6 - 17%),BMD升高(3 - 5%)。富含硝酸盐的饮食也有类似的保护作用(骨折风险降低7 - 74%,BMD增加8 - 84%)。随机对照试验也表明,硝酸盐可增加循环中的骨形成标志物;然而,尚未报道对骨折风险有影响,仅在一项研究中报道了BMD增加(8.8%)。硝酸盐转化为亚硝酸盐,然后再转化为NO(外源性NO),增加骨中的NO生物利用度。此外,硝酸盐可增加内皮型NO合酶(eNOS)的表达,从而增加骨中的内源性NO。硝酸盐衍生的NO通过NO/环磷酸鸟苷(cGMP)/蛋白激酶G(PKG)信号通路促进骨形成并减少骨吸收。除了增加NO的可用性外,硝酸盐还可能提高糖尿病患者的血浆胰岛素水平、降低高血糖并改善胰岛素抵抗,进一步促进硝酸盐对糖尿病性骨的抗骨质疏松作用。总之,基于NO的干预措施如硝酸盐可能在预防和治疗糖尿病性骨质疏松症中具有潜在作用。